SCHEMBL7940952

SCHEMBL7940952

CN1C(=O)CC(C)(c2cc(NC(=O)C3CNc4ccccc4O3)ccn2)N=C1N

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 14/20 0.43
HPGD P15428 2/20 0.42
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
MDM2 Q00987 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301738 0.88 NPC1 (0.49) HPGDALDH1A1NPC1TP53MAPT
SCHEMBL7941226 0.88 BACE1 (0.55) BACE1HPGD
SCHEMBL12301670 0.86 BACE1 (0.49) BACE1HPGD
SCHEMBL12445875 0.75 BACE1 (0.40) BACE1
SCHEMBL7941811 0.75 MAPT (0.50) BACE1HPGDALDH1A1NPC1TP53
SCHEMBL7944645 0.75 BACE1 (0.61) BACE1NPC1RAB9A
SCHEMBL7943459 0.75 BACE1 (0.42) BACE1
SCHEMBL7942862 0.75 BACE1 (0.56) BACE1HPGDALDH1A1NPC1TP53
SCHEMBL7944484 0.75 BACE1 (0.48) BACE1NPC1RAB9A
SCHEMBL7945205 0.74 BACE1 (0.61) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885HPGD 3195/4885ALDH1A1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.